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ABSTRACT

Kovar, Sarah E. M.S., Department of Biochemistry and Molecular Biology, Wright State
University, 2018. Discovery of small molecules blocking oncogenic K-Ras activity.

Ras proteins were the first human oncogenes discovered. Although Ras has been found
to be the most frequently mutated oncogene, there are currently no anti-Ras-specific
drugs available in the clinic. Ras is responsible for initiating cellular pathways that
include proliferation, survival, and apoptosis. There are three ubiquitously expressed
Ras isoforms in mammalian cells: H-, N-, and K-Ras. Interaction with the plasma
membrane is required for Ras biological activity. When Ras interaction with the plasma
membrane is blocked, Ras activity is inhibited.
Two compounds (from Dr. Ketcha, WSU Chemistry Department) were tested and shown
to dissociate K-Ras, but not H-Ras from the plasma membrane. The molecular
mechanism was found to be through phosphorylation of K-Ras Ser181. Furthermore,
these compounds block signal output of K-Ras, but not H-Ras, and inhibit the growth of
K-Ras-driven non-small cell lung cancer cells. Further characterization of these
compounds could lead to the development of anti-K-Ras drugs.
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Introduction

I.

Ras Proteins

A. Ras as a molecular switch

Ras is a small GTPase that works as a molecular switch (Papke & Der, 2017).
When bound with guanosine triphosphate (GTP), Ras is in the active
conformation, and when bound with guanosine diphosphate (GDP), Ras is in
the inactive conformation (Papke & Der, 2017). GTPase activating protein
(GAP) helps facilitate the innate Ras GTPase activity that converts GTP to GDP
causing Ras to take on the inactive conformation (Papke & Der, 2017).
Guanine exchange factor (GEF) assists in opening the Ras protein, allowing
the guanine nucleotide within the protein to be released (Hancock, 2003).
Since the concentration of GTP is approximately ten-fold higher in the cell
than GDP, it is statistically likely that GTP will fill the empty Ras molecule,
resulting in the activation of Ras (Papke & Der, 2017; Traut, 1994). Ras has
three ubiquitously expressed isoforms: H-, N-, and K-Ras (Hancock, 2003).
There are two splice variants of K-Ras: K-Ras 4A and K-Ras 4B (Zhou &
1

Hancock, 2018). Of these two variants, K-Ras 4B is the most commonly
expressed and will henceforth be called K-Ras (Stephen, Esposito, Bagni, &
McCormick, 2014). All three isoforms have a conserved structure within the
G domain but differ within the hypervariable region (HVR) (Figure 1)
(Hancock, 2003). The HVR is where the post-translational modifications occur
and is what dictates how the isoforms are trafficked and how they interact
with the plasma membrane (Hancock, 2003).

2

Figure 1. Ras isoforms. Three ubiquitously expressed isoforms of Ras, highlighting the
conserved domains and hypervariable region (HVR). The HVR is where posttranslational modifications, such as farnesylation, occur. The polybasic domain (PBD) of
K-Ras is highlighted here showing six consecutive lysine residues. Figure adapted from
(Hancock, 2003).
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B. Ras trafficking

Once Ras is translated in the cytosol, it undergoes several post-translational
modifications. First, it is farnesylated with a 15-carbon polyunsaturated
farnesyl chain attached at the cysteine residue within the C-terminal -CAAX
motif by farnesyltransferase (Zhou & Hancock, 2018). The farnesyl chain
allows Ras to attach to the membrane of the endoplasmic reticulum, where
the AAX tripeptide is removed by Ras converting enzyme and the cysteine is
further methylated by isoprenylcysteine carboxyl methyltransferase (Zhou &
Hancock, 2018). The H- and N- isoforms are palmitoylated and trafficked to
the plasma membrane by means of the classic vesicular pathway, whereas KRas only carries the single farnesyl chain and is trafficked to the plasma
membrane by an unclear pathway (Zhou & Hancock, 2018). Recently, it has
been shown that recycling endosomes are involved in maintaining K-Ras at
the plasma membrane (Schmick et al., 2014).

C. Ras signaling

To be biologically active, Ras must be localized to the plasma membrane
(Willumsen, Christensen, Hubbert, Papageorge, & Lowy, 1984). Epidermal
growth factor (EGF) binds with epidermal growth factor receptor (EGFR) at
4

the plasma membrane; this, in turn, recruits the GEF, Son of Sevenless (SOS),
to the plasma membrane, which binds with Ras leading to its activation
(Figure 2) (Fitzgerald et al., 2015; Iversen et al., 2014). Once Ras is activated,
it initiates important cellular pathways such as growth, proliferation, and
differentiation (Hancock, 2003). Among many other pathways, Ras is
responsible for initiating RAF/MAPK and PI3K/AKT/mTOR pathways that
activate cell proliferation by inciting the passage from Gap 1 to the synthesis
phase of the cell cycle (Nussinov, Tsai, & Jang, 2018a). K-Ras more
proficiently initiates the Raf/MAPK pathway, whereas H-Ras is more
proficient at initiating the PI3K pathway (Yan, Roy, Apolloni, Lane, & Hancock,
1998).
At the plasma membrane, Ras can be found as monomers, dimers, or
nanoclusters (Sarkar-Banerjee et al., 2017). Dimer formation is isoform
specific owing to the variations within the HVR of each isoform (Jang,
Muratcioglu, Gursoy, Keskin, & Nussinov, 2016; Zhou & Hancock, 2015).
Approximately 56% of Ras proteins are found as itinerant monomers or
dimers, and approximately 44% are found as fixed nanoclusters (Zhou &
Hancock, 2015). Nanoclustering is dynamic, not static, and is important for
Ras function (Plowman, Muncke, Parton, & Hancock, 2005).

5

Figure 2. Ras signaling. Activation of Ras at the plasma membrane involves
the epidermal growth factor (EGF) and receptor (EGFR) along with GEFs
such as SOS (not pictured). Two of the main Ras signaling pathways are
shown here, revealing the importance of Ras signaling for cell growth and
proliferation (Figure adapted from (Fitzgerald et al., 2015)).
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D. Unique properties of K-Ras

K-Ras is unique among the isoforms in structure, trafficking, and signaling
due to a polybasic domain (PBD) within the HVR that contains six lysine
residues (Hancock, 2003). This PBD helps K-Ras anchor to acidic, liquid
disordered microdomains at the plasma membrane, whereas H- and N-Ras
are found at zwitterionic microdomains (Nussinov, Tsai, et al., 2018a; Weise
et al., 2011; Zhou & Hancock, 2018). K-Ras associates with an anionic lipid
phosphatidylserine (PS) at the plasma membrane (Cho, Park, et al., 2012;
Yeung et al., 2008). Myristoylated alanine-rich C kinase substrate (MARCKS)
contains a basic domain that is comparable to the PBD of K-Ras and localizes
to the plasma membrane at phosphatidylinositol 4,5-bisphosphate (PIP2)
through electrostatic interactions (Wang et al., 2002). Though they contain
similar basic domains, K-Ras does not localize with PIP2 as MARCKS does
(Zhou & Hancock, 2018). PIP2 is a multivalent, highly charged lipid, whereas
PS is monovalent (Zhou & Hancock, 2018). The localization of K-Ras to PS is
more than simply electrostatic interaction, as originally thought; it is due to
the PBD favoring a disordered, pseudo-helical conformation that optimizes
the number of hydrogen bonds with PS (Zhou & Hancock, 2018).
Due to the positive charge of the PBD, K-Ras dimerization occurs at the
catalytic domains, whereas H-Ras dimerizes at the catalytic domain or the
HVR (Jang et al., 2016). K-Ras is the only isoform that forms actin-dependent
7

nanoclusters (Plowman et al., 2005). These structural and signaling
differences may elucidate why K-Ras is a stronger oncogene than the other
isoforms and why K-Ras knockout mice die during embryogenesis, but H- and
N-Ras mice do not (Johnson et al., 1997; Stephen et al., 2014).
K-Ras is the only isoform that binds with the primary calcium sensor,
calmodulin (Sorensen, Sondergaard, & Overgaard, 2013; Stephen et al.,
2014). Calmodulin recruits K-Ras to PI3K, forming a complex that fully
activates PI3K (Nussinov, Tsai, et al., 2018a; Nussinov, Tsai, & Jang, 2018b;
Nussinov, Zhang, Tsai, & Jang, 2018). This full activation of PI3K, along with
the proficiency of activating Raf, may explicate why K-Ras mutations are
common among a variety of cancers (Nussinov, Tsai, et al., 2018b; Prior,
Lewis, & Mattos, 2012).

E. Ras mutations in cancer

The first oncogene identified was the Ras gene, and since then, Ras has been
characterized as the most recurrently mutated oncogene (Stephen et al.,
2014). K-Ras is the most commonly mutated isoform and is found in 90% of
pancreatic tumors (Prior et al., 2012). The most common mutations in all
isoforms are found at codons 12, 13, or 61 (Prior et al., 2012). Mutations at
these residues disrupt the intrinsic GTPase activity, or GAP interaction and
create an inability to hydrolyze GTP to GDP; either scenario results in
8

constitutively active Ras, triggering unregulated cellular proliferation and
differentiation (Prior et al., 2012). A small number of mutations occur at
switch III (Figure 3) and enhance nanoclustering, which in turns modifies Ras
signaling (Solman et al., 2015). Different mutations cause different signaling
changes (Ihle et al., 2012). For example, in non-small cell lung cancer cells
(NSCLCs), mutations at amino acid residue 12 from glycine (G) to cysteine (C)
or valine (V) cause an increase in Ral/GDS, whereas mutation to aspartic acid
(D) causes an increase in PI3K signaling (Ihle et al., 2012).

9

Figure 3. K-Ras domains. Switch I, switch II, and switch III of K-Ras are shown in relation to
the HVR. A small number of mutations occur at switch III enhancing Ras nanoclustering
(Figure adapted from (Solman et al., 2015)).
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F. Ways to target Ras

Since Ras was first discovered as an oncogene, efforts have been made to
therapeutically target Ras. There is still, however, no anti-Ras drug in the
clinic (Papke & Der, 2017). The first attempt at targeting Ras was to block the
post-translational farnesylation with farnesyltransferase inhibitors, stopping
Ras interaction with the plasma membrane, thereby blocking Ras activity.
However, it was proved ineffective for K-Ras due to an alternative
prenylation by geranylgeranyltransferase that restored K-Ras plasma
membrane interaction and activity (Stephen et al., 2014). Another approach
was to block Ras downstream effector proteins. Despite initial promises,
targeting Ras downstream effectors proved to be more complicated. For
example, Raf inhibitors were reported to paradoxically activate, instead of
inhibit, the Ras/MAPK signaling pathway (Cho, Kasai, et al., 2012; Heidorn et
al., 2010).
Furthermore, substantial cross talk between Ras effector pathways exist. ERK
inhibition causes compensatory activation of PI3K/Akt signaling, whereas
inhibition of PI3K signaling increases ERK signaling (Collisson et al., 2012;
Soares et al., 2015). Concomitant inhibition of MAPK and PI3K/Akt signal
pathways failed in clinic due to high toxicity issues. Due to these efforts, Ras
has been deemed as an undruggable target (Stephen et al., 2014). However,
there has been a resurgence in the field to find a viable way to target Ras.
11

Since K-Ras is the most commonly mutated isoform, the emphasis is being
placed on targeting K-Ras (Papke & Der, 2017). There are five prevalent
approaches to targeting K-Ras: 1) disrupting K-Ras interactions with
effectors; 2) altering membrane localization; 3) inhibiting downstream
effectors; 4) synthetic lethality; and 5) altering metabolism within the cancer
cell (Figure 4) (Papke & Der, 2017). This study will focus on ways in which KRas plasma membrane localization is altered.

12

Figure 4. Five approaches to target K-Ras. These are the five most common approaches for
targeting K-Ras. Of these five, this study will focus on targeting Ras localization (Figure
adapted from (Papke & Der, 2017)).

13

II.

Natural Compounds for the Treatment of Disease

A. Chalcones: a naturally derived treatment

There is a recent proclivity to look to nature for compounds found in edible
plants and traditional herbal medicines to develop new therapeutics
(Carradori, D'Ascenzio, Chimenti, Secci, & Bolasco, 2014). One compound
class that is gaining in popularity is the chalcone. Chalcones are found in
fruits, vegetables, and other common edible plants (Chimenti et al., 2009;
Orlikova, Tasdemir, Golais, Dicato, & Diederich, 2011). They are gaining
popularity due to their diverse health benefits, including but not limited to,
anti-viral, anti-inflammatory, anti-bacterial, anti-oxidative, and anti-cancer
properties (Bandgar, Gawande, Bodade, Totre, & Khobragade, 2010;
Chimenti et al., 2009; Jung, Lee, Min, Jung, & Oh, 2017; Orlikova et al., 2011).
They have been shown to be cytotoxic to a variety of cancer cells, such as
colorectal and lung cancers (Syam, Abdelwahab, Al-Mamary, & Mohan,
2012). Chalcones are of particular importance in developing treatments due
to their natural origin and comparatively low side effects (Bandgar et al.,
2010; Jung et al., 2017).
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B. Chalcones inhibit monoamine oxidase

One of the major known biological effects of chalcones is the inhibition of the
enzyme monoamine oxidase (MAO) (Hammuda et al., 2016). Two types of
MAO enzymes, MAO-A and MAO-B, are found at the mitochondrial
membrane and are flavin adenine dinucleotide (FAD)-dependent (Hammuda
et al., 2016). These enzymes catalyze the deamination of monoamine
neurotransmitters such as serotonin, dopamine, and norepinephrine
(Carradori et al., 2014; Herraiz, Flores, & Fernandez, 2018). Due to the reoxidation of the FAD cofactor in this enzymatic reaction, hydrogen peroxide
is produced (Minders, Petzer, Petzer, & Lourens, 2015). Hydrogen peroxide is
known to cause oxidative stress, therefore, inhibitors of MAO act as a
neuroprotectant by reducing the amount of hydrogen peroxide produced
from this reaction (Hammuda et al., 2016). An increase in this kind of
oxidative stress is linked with neurodegeneration found in Alzheimer’s and
Parkinson’s diseases (Cao et al., 2009). In clinic, several MAO-B inhibitors are
used to treat patients with Parkinson’s disease (Giladi, Asgharnejad, Bauer,
Grieger, & Boroojerdi, 2016). In addition, since MAOs breakdown serotonin,
MAO inhibitors have been used as antidepressants (Satram-Maharaj et al.,
2014). Interestingly, depression has been associated with an increased risk
for Alzheimer’s disease, suggesting a possible role for MAO activity in
depression and Alzheimer’s disease (Cao et al., 2009).
15

C. Chemical structure of chalcones

The basic chemical structure of chalcones is an open chain flavonoid system
where a three-carbon α,β-unsaturated carbonyl joins two aromatic rings in a
conjugated system (Figure 5) (Chimenti et al., 2009; Jung et al., 2017;
Orlikova et al., 2011). In nature, chalcones are produced through the
enzymatic reaction of chalcone synthase; however, in a laboratory setting,
chalcones are synthesized through a classic base-catalyzed Claisen-Schmidt
condensation reaction of an aldehyde with a ketone in an alcoholic (polar)
solvent (Jung et al., 2017; Orlikova et al., 2011). This is important since they
can be synthesized by a rather simple reaction that can be tailored for
efficiency and production with a high percentage yield (Jung et al., 2017;
Orlikova et al., 2011). The broad biological activity, low side effects, and
production potential validates the appeal of chalcones as a scaffold for drug
development.

16

Figure 5. Basic structure of chalcones. The basic chemical structure of chalcones consists of an open chain
flavonoid system with a three-carbon α,β-unsaturated carbonyl joining two aromatic rings labeled A and B
(Figure adapted from (Chimenti et al., 2009)).
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D. Substituent groups affect biological activity

There are plethoras of studies, which show how synthesizing novel chalcones
with various constituent groups can alter the biological activity and increase
the efficacy of the compound. Jung and colleagues investigated novel
chalcones against four areas of interest: free radical scavenging, cell viability,
nitric oxide (NO) generation, and neuroprotective qualities (Jung et al., 2017).
They found that a major player in the biological efficacy of the novel
chalcones was a para-position methoxy group; this helped to redistribute the
electronic density within the conjugated system and increased the
compound’s effectiveness (Jung et al., 2017). Mathew et al found fluorinated
methoxylated chalcones to be reversible, competitive MAO-B inhibitors
(Mathew et al., 2015). Later, they found that methoxylated chalcones with a
substitution on the para-position of the B ring are effective reversible,
competitive MAO-B inhibitors (Mathew et al., 2017).
In this study, two novel chalcones, compound CF-1-32 (32) and compound
CM-1-101 (101), were synthesized based on the core chalcone structure
(Figure 6). Both compounds contain a nitro group in the para-position of the
A ring. This group is an electron withdrawing group that pulls electronic
density away from the aromatic ring. The nitro group also acts as a hydrogen
bond acceptor. Compound 32 contains three methoxy groups in the B ring

18

that can donate electrons due to the lone pairs on the oxygen. Compound
101 contains two ortho fluorine groups in the B ring.

19

A

B

Compound 32

Compound 101
Figure 6. Structure of compound 32 and compound 101. Compound 32 (upper panel) has a paraposition nitro group on the A ring that can serve as a hydrogen bond acceptor. There are three
methoxy groups on the B ring. Compound 101 (lower panel) also has a para-position nitro group
on the A ring. The B ring contains two ortho fluorine groups. A and B rings labeled, respectively.
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III.

Hypothesis and Specific Aims

Chalcones have been demonstrated to have anticancer properties and are a
viable scaffold for creating new therapeutics (Chimenti et al., 2009). They
have been shown to be cytotoxic to a variety of cancers, including colorectal
and lung cancers (Syam et al., 2012). Mislocalizing K-Ras from the plasma
membrane reduces signal output and is a potential target for K-Ras-specific
therapies (Hancock, 2003). We hypothesize that chalcones’ anti-cancer
activity in lung and colorectal cancers is through disrupting K-Ras plasma
membrane interaction, thereby blocking its activity. This study ascertained
the effects of two novel, chalcone-based compounds against oncogenic
mutant K-Ras, K-RasG12V. This was accomplished through three aims: 1)
characterizing the effect of compounds 32 and 101 in K-Ras plasma
membrane interaction; 2) elucidating the mechanism of action of compounds
32 and 101; and 3) characterizing the anticancer activity of compounds 32
and 101 in lung cancer cells. The ultimate goal is to find clinical treatments to
K-Ras driven cancers and finally target this seemingly “undruggable” protein.

21

Methods and Materials

I.

Cell Culture

Madin-Darby Canine Kidney (MDCK) cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco; Cat# 10569-010) supplemented
with 10% Fetal Bovine Serum (FBS) (Gibco; Cat# F0600-050) and 2mM LGlutamine (GenDEPOT; Cat# CA009-010). Non-small cell lung cancer cells
(NSCLCs): H522, H1975, H1299, A549, H23, H441, and H358 were maintained
in RPMI-1640 (ATCC; 30-2001) with 10% FBS and 2mM L-Glutamine. A noncancerous human lung epithelial cell line, BEAS-2B was cultured in complete
Bronchial/Tracheal Epithelial Cell Serum-Free Growth Medium (Cell
Applications; Kit Cat# 511K-500; medium Cat# 510-495) prepared aseptically
with the addition of growth supplements 1-4 (511-GS1, 511-GS2, 511-GS3,
511-GS4). Cell lines periodically tested for mycoplasma (Lonza MycoAlert
Mycoplasma Detection Kit). All cell lines were maintained in a 37°C incubator
with 5% CO2 injection.
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II.

Antibodies

Phospho-Akt (Ser473) (D9E) XP (Cat#4060), phospho-AMPKα (Thr172) (40H9)
(Cat#2535), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP
(Cat#4370), p44/42 MAPK (Erk1/2) (L34F12) (Cat#4696), Akt (pan) (40D4)
(Cat#2920), phospho-eNOS (Ser1177) (C9C3) (Cat#9570), and phosphoMARCKS (Ser152/156) (Cat#2741) antibodies were purchased from Cell
Signaling Technology (Danvers, MA). GAPDH (Cat#60004-1-Ig; clone #1E6D9),
beta actin (Cat#60008-1-1g) and GFP Tag (Cat#66002-1-Ig; clone #1E10H7)
antibodies were purchased from Proteintech (Rosemont, IL).

III.

Production of Compounds

Dr. Daniel Ketcha (WSU, Chemistry Dept.) and his lab produced compounds
CF-1-32 (32) and CM-1-101 (101). Briefly, the compounds were produced via
the classic base catalyzed Claisen-Schmidt condensation reaction in ethanol
(Jung et al., 2017; Orlikova et al., 2011). Dried compounds were
reconstituted to a 50mM or 100mM stock solution in DMSO. From the stock
solution, various concentrations of aliquots were prepared by serial dilutions
with DMSO.
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IV.

K-Ras Plasma Membrane Localization Assay

MDCK cells stably co-expressing GFP-K-RasG12V, GFP-K-RasG12V AAA, GFPK-RasG12V S181A, GFP-H-RasG12V, or GFP-LactC2 with mCherry-CAAX were
used to show the localization of Ras or PS under drug treatment.
a. Seeding and treatment of cells
On day one, 1.5mL media was applied to the wells of a 12-well plate. A glass
coverslip was placed at the bottom of each well. Cells were evenly seeded at
2.5x105, 2.75x105, or 3x105 cells per well. Next day, the cells were washed
once with media. Next, 2mL of complete growth media with different
concentrations of drugs were applied to each well. For a control well, an
equal volume of DMSO was used.
b. Fixing cells
On day four, 48h after the drug treatment, cells were washed twice with ice
cold 1X phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde
(PFA) for 30 min in the dark. The cells were washed twice with ice cold 1X
PBS and incubated in the dark in 50mM NH4Cl for 10 min. After incubation,
the coverslips were washed in PBS and then in MilliQ dH2O. The coverslips
were mounted onto slides with mowoil, a mounting media, and placed in the
dark overnight. Next day, the slides were imaged or stored at 4°C.
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c. Confocal imaging
Images were taken using an Olympus Fluoview FV1000. Three representative
images were taken of each coverslip. For best results, images were taken
within two days of fixation.
d. Analysis
GFP localization was analyzed using ImageJ version 1.51k (NIH, USA) to
obtain a Manders coefficient value (Manders E.M., 1993). The three
representative images of each coverslip were averaged to obtain a value for
each condition. Here, Manders coefficient shows the number of red pixels
colocalized with green pixels, divided by the total number of red pixels,
which gives the fraction of red pixels colocalized with green pixels.

V.

Western Blot

a. Seeding and treatment of cells
On day one, cells (MDCK or NSCLC) were seeded onto a 6-well plate with
3x105 cells in 2mL of appropriate complete growth media in each well. Drugs
were administered to cells in varying concentrations, 24h after seeding.
DMSO was used as a control.
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b. Harvesting whole cell lysates
48h after drug treatment, cells were washed twice with ice cold 1X PBS. Cells
were incubated on ice in lysis buffer B (50mM Tris, pH 7.5, 75mM NaCl,
25mM NaF, 5mM MgCl2, 5mM EGTA, 3.3µg-µL-1 aprotinin, 0.1mM Na3VO4,
0.1mg-mL-1 leupeptin, 1mM DTT (except for samples that will also be used
for the monoamine oxidase assay), 1% NP-40) for at least 5 min. The amount
of lysis buffer used was dependent on the confluency of the wells, with more
buffer used at higher confluencies. Generally, 300-600µL of lysis buffer was
used per well. The cells were scraped and collected into pre-chilled tubes.
The tubes were vortexed and incubated on ice for 10 min with vortexing in a
5 min interval, and centrifuged at full speed for 10 min in 4°C with a benchtop centrifuge. The supernatant was transferred into a new, pre-chilled tube.
Samples were aliquoted to avoid freeze/thaw and stored at -80°C. Protein
amount was quantified by BCA assay (Reagent A Cat# PI23221/PI23223,
Reagent B Cat# PI23224, Thermo Fisher Scientific).
c. Preparation of samples
Samples were prepared with 20µg of protein. Samples were denatured at
95°C for 5 min. Next, the samples were either loaded into a gel or stored at 20°C until ready for loading.
d. Running gels
Proteins were separated via SDS polyacrylamide gel electrophoresis (PAGE).
GFP-K-Ras/H-Ras, pAMPK, ppERK, pAKT, total ERK, total AKT, beta actin, and
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GAPDH were separated on 10% gels while pMARCKS and peNOS were
separated on 8% and 6% gels, respectively. Proteins were transferred to
PVDF Immun-Blot membranes (Bio-Rad; Cat# 1620177; Hercules, CA) using a
semi-dry transfer system (Model: Trans-Blot SD Semi-Dry Transfer Cell, BioRad). Proteins were transferred at 15V for 30 min per membrane for proteins
less than 100 kDa and 60 min per membrane for proteins larger than 100
kDa. Membranes were then incubated at room temperature for 1h in BSA
blocking buffer (5% BSA in TBST (10mM Tris, pH 7.5, 150mM NaCl, 0.1%
Tween 20)) for phospho-proteins or in milk blocking buffer (5% dry, non-fat
milk in TBST) for non-phospho-proteins. Membranes were then probed for
primary antibodies in the appropriate blocking buffer and incubated O/N at
4°C. The following dilutions were used for primary antibodies: GFP (1:4,000),
pAMPK (1:1,000), ppERK (1:4,000), pAKT (1:1,000), total ERK (1:1,000), total
AKT (1:2,000), GAPDH (1:8,000), beta actin (1:5,000), pMARCKS (1:1,000),
and peNOS (1:1,000). The membranes were washed 3 times in TBST for 10
min then incubated with an appropriate secondary antibody in the same
blocking buffer as the primary antibody for 1h at room temperature. A
mouse secondary antibody (goat anti-mouse IgG (H+L) horseradish
peroxidase (HRP) conjugate, G21040, Invitrogen, Carlsbad, CA) was used at a
dilution of 1:5,000 for GAPDH and 1:2,000 for all other proteins. A rabbit
secondary antibody (goat anti-rabbit IgG (H+L) HRP conjugate, G21234,
Invitrogen) was used at a dilution of 1:5,000. The membranes were washed 3
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times with TBST for 10 min. The membranes were developed with Super
Signal West Pico Plus Chemiluminescent Substrate (34578, Thermo Scientific,
Rockford, IL) with the addition of Super Signal West Dura Extended Duration
Substrate (34076, Thermo Scientific) for most proteins, excluding GAPDH, at
a 4:1 ratio. Images were taken on an Amersham Imager 600 (GE Healthcare
Life Sciences, Marlborough, MA). Membranes were stained with Coomassie
blue (Brilliant Blue R-250, Fisher BioReagents, Fairlawn, NJ) to verify equal
loading.
e. Analysis
Images were analyzed using ImageJ by calculating the intensity of the bands
of interest. Each lane was normalized to the control (DMSO) lane of each gel.

VI.

Monoamine Oxidase Assay

Cells were plated, treated with compound 32, compound 101, or known
MAO inhibitors, and harvested as described in section V a-b with the
exception that in step b, lysis buffer B was made without DTT due to the
product of this assay being unstable in thiols. The assay was performed using
the Amplex Red Monoamine Oxidase Assay Kit (A12214) (Molecular Probes,
Eugene, OR). All reagents were prepared according to manufacturer’s
instructions. Samples were made with 66µg of protein from the whole cell
lysates in 1X reaction buffer for a final volume of 165µL. A positive control
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(10µM H2O2 in 1X reaction buffer) and a negative control (1X reaction buffer)
were used. Using a black 96-well plate, 50µL of 200µM Amplex Red reagent
with 2U/mL HRP and 2mM p-Tyramine were added to each well. Next, 50µL
of sample/controls were aliquoted into each well (3 wells per sample) and
pipet mixed. The plates were then incubated in the dark at room
temperature for 30 min. The fluorescence intensity was read using a Synergy
H1 microplate reader (BioTek) with excitation at 540nm and emission
detection at 590nm. The plates were incubated for an additional 30 min in
the dark at room temperature and a second fluorescence reading was taken.

VII.

Proliferation Assay

On day one, lung cells (NSCLCs or BEAS-2B) were seeded on a 96-well plate at
1x104 cells per well with 100µL of appropriate complete growth media. 24h
later, the media was replaced with the addition of drugs at different
concentrations. Fresh, complete growth media with different concentrations
of drugs were replaced every 24h for 3 days (van der Hoeven et al., 2013).
The media was then removed and 100µL of 1X dye binding solution
(CyQUANT NF Cell Proliferation Assay Kit C35006, Molecular Probes, Eugene,
OR) was applied to each well. Plates were incubated at 37°C for 30 min and
the fluorescence intensity was read with excitation at 485nm and emission
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detection at 530nm. The plates were further incubated for an additional 30
min at 37°C and a second fluorescence intensity was recorded.

VIII.

Fractionation Assay
a. Seeding and treatment of cells
On day one, MDCK K-RasG12V or H-RasG12V cells were seeded onto 6cm
dishes with 6.63 x 105 cells in 5mL of appropriate complete growth media.
Drugs were administered to cells in different concentrations, 24h after
seeding. DMSO was used as a control.
b. Harvesting and collecting fractions
48h after drug treatment, cells were washed twice with ice-cold 1x PBS. Lysis
buffer A (10mM Tris, pH 7.5, 25mM NaF, 5mM MgCl2, 1mM EGTA, 10µg-µL-1
aprotinin, 0.1mM Na3VO4, 0.1mg-mL-1 leupeptin, 1mM DTT) was added to
each plate in an amount that was dependent on the confluency of the cells,
normally 500µL. Cells were scraped and collected into pre-chilled tubes and
incubated on ice for 10 min. Cells were broken apart by forcefully passaging
through a 23-gauge needle 30 times. Lysates were centrifuged at 1500 x g for
10 min at 4°C with a bench-top centrifuge. The supernatant containing the
membrane and cytosol was carefully transferred to a pre-chilled,
ultracentrifuge tube. The tubes were spun using a Sorvall Discovery MX120SE
Ultracentrifuge (Thermo Scientific, Waltham, MA) at 100,000 x g for 60 min
at 4°C. The supernatant containing the cytosolic fraction was transferred to a
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pre-chilled tube. The pellet was washed twice with 500µL buffer A. 100µL
buffer A was aliquoted to the pellet and sonicated with a Sonic
Dismembrator (model FB120, Fisher Scientific, Pittsburgh, PA) using 10
strokes, making sure the pellet was broken apart. This lysate, containing the
membrane fraction, was transferred to a pre-chilled tube. Lysates were
analyzed for protein concentration by Bradford Assay (Bio-Rad Protein Assay
Dye Reagent Concentrate, Cat #5000006, Bio-Rad Laboratories). Samples
were made, and gels were run according to section V c-d with the exception
that 10µg of protein was used.
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Results

I.

Characterizing the Effect of Compounds 32 and 101 in K-Ras Plasma
Membrane Interaction

As stated previously, K-Ras must be localized to the plasma membrane for
biological activity (Hancock, 2003). Targeting K-Ras localization at the plasma
membrane is a valid avenue for potential K-Ras-specific drug development
(Cho, Casteel, et al., 2016; Cho, Park, et al., 2012; van der Hoeven et al.,
2013). In this section, the effects of compound 32 and compound 101 on KRas localization were characterized.

A. Manders coefficient

To quantitate K-Ras mislocalization from the plasma membrane, Manders
coefficient analyses, which determines colocalization of fluorophores in dualcolor images, was used (Manders E.M., 1993). Manders coefficient is a
popular and scientifically accepted way of analyzing images; this method
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takes out the subjectivity of the classical way of analyzing colocalization
through visualizing an overlap in fluorescence through color change
(Pastorek, Sobol, & Hozak, 2016; Reitan, Sporsheim, Bjorkoy, Strand, &
Davies Cde, 2012). In our case, the colocalization of GFP-tagged protein of
interest (K-Ras or H-Ras; green) with mCherry-CAAX (an endomembrane
marker; red) was determined (Choy et al., 1999). After confocal microscopy
images were taken, ImageJ software was used to determine the fraction of
red pixels colocalized with green pixels. A low coefficient shows that there is
low colocalization of red pixels and green pixels. A high Manders coefficient
means there is a high number of green pixels (in this case, GFP-Ras)
colocalized with red pixels (mCherry-CAAX). Since K-Ras is localized to the
plasma membrane, a high coefficient equates to K-Ras being mislocalized to
the endomembranes from the plasma membrane (Figure 7).
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Figure 7. A visual explanation of analyzing K-Ras localization using Manders coefficient.
MDCK cells stably co-expressing GFP-KRasG12V were treated with DMSO (control) or 10M fendiline, a drug that
mislocalizes K-Ras from the plasma membrane, for 48h. Cells were fixed with 4% PFA and imaged using a confocal
microscope. ImageJ software was used to generate Manders coefficient.
Determining Manders coefficient is an objective way to analyze the colocalization of two different fluorescently
labeled molecules. In this case, GFP-Ras is analyzed against the localization of mCherry-CAAX (an endomembrane
marker). This is a more objective way to quantitate colocalization than merely visually verifying a shift in color
when the fluorescent labels overlap.
A low Manders coefficient value, shown in the bottom right corner of the image, shows relatively low
colocalization of GFP-K-Ras with mCherry-CAAX (left panel). A high Manders coefficient shows a high colocalization
of GFP-K-Ras with mCherry-CAAX (right panel). From this, we can conclude the localization of Ras. A low coefficient
means that Ras is localized to the plasma membrane, whereas a high coefficient means that Ras has been
mislocalized intracellularly to the endomembranes.
34

B. K-Ras localization

K-Ras is responsible for initiating critical cellular signals, such as growth,
proliferation, and differentiation (Hancock, 2003). K-Ras must be localized to
the plasma membrane to be biologically active, therefore, removing K-Ras
from the plasma membrane will reduce the downstream signaling output
(Hancock, 2003). Compounds that can lead to the mislocalization of K-Ras are
potential targets for K-Ras specific therapies (Cho, Casteel, et al., 2016; Cho,
Park, et al., 2012; Cho, van der Hoeven, et al., 2016). For that reason, when
looking at a possible compound to target K-Ras, it is useful to determine the
effects of the compound on K-Ras localization.
Compound 32 and compound 101 were analyzed to determine their
influence on K-Ras localization and downstream signaling. First, MDCK cells
were used to determine K-Ras localization. MDCK cells were chosen as they
show clear Ras plasma membrane localization and the columnar morphology
is well suited for automated imaging. This makes it easier to visualize
changes in localization.
MDCK cells stably co-expressing GFP-K-RasG12V and mCherry-CAAX were
incubated with DMSO or one of the two compounds in varying
concentrations for 48h, which is a sufficient time interval to document
changes in localization brought on by drug treatment (Cho, Park, et al.,
2012). After incubation, the cells were fixed with 4% PFA and imaged with a
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confocal microscope. Both compound 32 and compound 101 mislocalized KRas (Figure 8A). With increasing concentration of either compound, there
was an increase in Manders coefficient (Figure 8B). The IC50s of compound 32
and 101 derived from the Manders coefficients were found to be 4.8 µM,
and 9.2 µM, respectively.
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Figure 8. The effect of compound 32
and compound 101 on K-Ras
localization. MDCK cells stably coexpressing GFP-K-RasG12V and
mCherry-CAAX were treated with
compound 32 (upper panel) or
compound 101 (lower panel) for 48h
(A). The cells were fixed with 4% PFA
and imaged with a confocal microscope.
Manders coefficient values were
determined for each compound and IC50
values were calculated (B). K-Ras
mislocalization (high Manders
coefficient value) increases with
increasing compound concentration.
The IC50 values for compound 32 and
compound 101 were 4.8 µM and 9.2
µM, respectively.
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C. H-Ras localization

K-Ras is unique among the three Ras isoforms in structure, plasma
membrane anchorage, and trafficking, whereas N- and H-Ras are very similar
in these areas (Hancock, 2003). It is important to elucidate if a compound is
K-Ras isoform-specific. This information could help to reveal the mechanism
of action and give insight into isoform-specific therapeutics.
Similarly, to the K-RasG12V cells previously mentioned, MDCK cells stably coexpressing H-RasG12V and mCherry-CAAX were treated with DMSO,
compound 32, or compound 101 for 48h. The H-Ras mutation is the same
G12V mutation found in the K-Ras cells. After treatment, these cells were
fixed with 4% PFA and imaged using confocal microscopy.
Compound 32 and 101 had a trivial effect on H-Ras cells (Figure 9). These
cells maintained a lower Manders coefficient even with a higher
concentration of compound. At 50 µM of compound 32, K-RasG12V cells
gave a Manders value of 0.60, whereas H-RasG12V cells gave a value of 0.46.
Similarly, 50 µM of compound 101 showed a value of 0.77 for K-RasG12V
cells and 0.38 for H-RasG12V cells. Compound 32 and compound 101
mislocalize K-Ras from the plasma membrane at concentrations of 25 µM
and 50 µM but do not mislocalize H-Ras at these same concentrations. These
data suggest that the effects of compounds 32 and 101 are specific to K-Ras,
but not H-Ras.
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Figure 9. Compounds 32 and 101 do not disrupt H-Ras plasma membrane localization.
Confocal microscopy images showing MDCK cells stably co-expressing mCherry-CAAX and GFPK-RasG12V or -H-RasG12V cells treated with compound 32 (A) or 101 (B) for 48 h at various
concentrations. K-RasG12V shows mislocalization at 25 µM and 50 µM with high Manders
coefficient values of 0.77 and 0.60, respectively. H-RasG12V does not show this same pattern
and has lower Manders coefficient values of 0.41 and 0.46. For compound 101, K-RasG12V
shows mislocalization at 25 µM and 50 µM with high Manders coefficient values of 0.72 and
0.77, respectively. H-RasG12V does not show this same pattern and has lower Manders
coefficient values of 0.41 and 0.38.
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D. Mislocalizing K-Ras

Recently, two molecular mechanisms by which K-Ras can be mislocalized
from the plasma membrane have been identified. The first is to disrupt PS at
the plasma membrane (Cho, Park, et al., 2012; Cho, van der Hoeven, et al.,
2016; Yeung et al., 2008). The second mechanism is through K-Ras
phosphorylation (Cho, Casteel, et al., 2016).
i.

K-Ras localization with PS

It has previously been shown that K-Ras localizes with PS at the
plasma membrane, and that the mislocalization of PS causes K-Ras
mislocalization (Cho, Park, et al., 2012; Cho, van der Hoeven, et al.,
2016; Yeung et al., 2008). Fendiline, a Ca2+ blocker, reduces cellular PS
levels, thereby mislocalizing K-Ras from the plasma membrane (Cho,
van der Hoeven, et al., 2016). It was also shown that reintroduction of
exogenous PS to fendiline-treated cells translocated K-Ras back to the
plasma membrane (Cho, van der Hoeven, et al., 2016).
To visualize the localization of PS, a fluorescently labeled C2 domain
of glycoprotein, lactadherin (Lact-C2), that specifically binds to PS, is
used (Yeung et al., 2008). MDCK cells stably co-expressing GFP-LactC2 and mCherry-CAAX were treated with DMSO, compound 32, or
compound 101 for 48h. The cells were fixed with 4% PFA and imaged
using confocal microscopy.
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Compound 32 and compound 101 did not mislocalize GFP-LactC2 as
was seen in the K-Ras cells (Figure 10). Compound 32 showed similar
Manders coefficient values across the drug treatment. Control cells
(DMSO-treated) gave a value of 0.46, while compound 32 treatment
with 25 µM and 50 µM gave values of 0.45 and 0.42, respectively. PS
is located in the plasma membrane, as well as other intracellular
membranes. Due to this, cells expressing GFP-Lact-C2 will have a
higher Manders coefficient value than cells expressing GFP-KRasG12V. This is why the Lact-C2 control cells have a higher value
than the K-RasG12V control cells. Similar effects were observed with
compound 101. A Manders coefficient value for control cells was
0.46, while compound 101 treatment with 25 µM and 50 µM were
0.49 and 0.43, respectively. Taken together, this data show that
compounds 32 and 101 do not perturb cellular distribution of PS,
suggesting the mechanism by which these compounds mislocalize KRas is independent of PS.
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Figure 10. Compounds 32 and 101 do not mislocalize PS. MDCK cells stably co-expressing GFP-Lact-C2
and mCherry-CAAX were treated with compounds 32 or 101 for 48h, and cells were fixed with 4% PFA
and imaged using confocal microscopy. Manders coefficient values for the compound-treated cells are
similar to control (DMSO-treated) cells.
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ii.

K-Ras phosphorylation

K-Ras interacts with the recycling endosome for maintaining its
plasma membrane localization; phosphorylation of K-Ras at amino
acid residue Ser181 has been shown to alter recycling endosome
interaction, resulting in K-Ras mislocalization from the plasma
membrane (Cho, Casteel, et al., 2016; Schmick et al., 2014). Once this
site is phosphorylated, electrostatic interactions of the negative
phosphate group and the anionic head groups of phospholipids in the
recycling endosome disrupt the ability for K-Ras to localize at the
membrane (Cho, Casteel, et al., 2016).
To test whether compounds 32- and 101-mediated K-RasG12V
mislocalization from the plasma membrane occurs through K-Ras
phosphorylation, MDCK cells stably co-expressing GFP-K-RasG12V
AAA and mCherry-CAAX were treated with various concentrations of
compound 32 or compound 101 for 48h. K-Ras has three putative
phosphorylation sites, serine 171, serine 181, and threonine 183
(Bivona et al., 2006). These residues were point-mutated to alanines
(AAA mutant), making K-Ras immune to phosphorylation (Cho,
Casteel, et al., 2016). After the treatment, the cells were fixed with
4% PFA and imaged using a confocal microscope.
Figure 11 shows that with treatment of either compound 32 or
compound 101, K-Ras remains localized at the plasma membrane.
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Since these K-Ras mutants cannot be phosphorylated, the mechanism
by which compounds 32 and 101 mislocalize K-Ras must be
phosphorylation-dependent.
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Figure 11. Compounds 32 and 101 do not mislocalize K-RasG12V AAA mutant from the
plasma membrane. MDCK cells stably co-expressing GFP-K-RasG12V AAA mutant and
mCherry-CAAX were treated with compounds 32 and 101 for 48h; cells were fixed with 4%
PFA and imaged using a confocal microscope. K-RasG12V AAA mutant is resistant to
phosphorylation since its putative phosphorylation sites Ser171, Ser181, and Thr183 have
been mutated to Ala. The low Manders Coefficient values of these images indicate that K-Ras
is not mislocalized when these sites cannot be phosphorylated.
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To further elucidate the specific phosphorylation site, MDCK cells stably
co-expressing GFP-K-RasG12V Ser181Ala (S181A) and mCherry-CAAX
were treated with compound 32 or compound 101 for 48h. Cells were
fixed with 4% PFA and imaged using a confocal microscope.
Our data show that K-RasG12V S181A was not mislocalized after the
treatment (Figure 12). The Manders coefficient values for compound 32
treated cells were 0.34 and 0.38 for 25 and 50 µM, respectively, whereas
DMSO treated control cells gave a value of 0.32. A similar trend was seen
for compound 101 treated cells. Cells treated with 25 or 50 µM of
compound 101 gave values of 0.33 and 0.40, respectively. The DMSO
treated cells gave a value of 0.31. These results show that when
phosphorylation at S181 is blocked, compounds 32 and 101 do not
mislocalize K-Ras. Therefore, the mechanism by which compound 32 and
compound 101 mislocalize K-Ras is through the phosphorylation of
Ser181.
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Figure 12. Compounds 32 and 101 do not mislocalize K-RasG12V S181A mutant from the
plasma membrane. MDCK cells stably co-expressing GFP-K-RasG12V S181A and mCherry-CAAX
were treated with compounds 32 and 101 for 48 h, and cells were fixed with 4% PFA and
imaged using a confocal microscope. Inserted values indicate Manders coefficients of KRasG12V S181A and mCherry-CAAX.
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E. Tracking K-Ras localization

To further validate K-Ras plasma membrane mislocalization by compounds
32 and 101, we examined K-Ras interaction with cellular membranes using a
cellular fractionation assay. MDCK cells stably expressing GFP-K-RasG12V or
GFP-H-RasG12V were treated with compound 32 for 48h. Cells were
harvested and fractionated into cytosolic and membrane fractions. Fractions
were immunoblotted to measure GFP-Ras associated with either the
membrane or cytosolic fractions.
Figure 13 shows that when treated with compound 32, the cytosolic fraction
of K-RasG12V increased significantly with treatment at 10 µM and 50 µM.
However, there is no significant change with H-RasG12V. Taken together
with the confocal data from Figures 8 and 9, these data show that compound
32 mislocalizes K-RasG12V, but not H-RaG12V from the plasma membrane to
other cellular membranes and cytosol.
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Figure 13. K-Ras increases in the cytosol with treatment of compound 32. MDCK cells
stably expressing GFP-K-RasG12V or GFP-H-RasG12V were treated with compound 32 for
48h. Cells were harvested, fractionated into cytosolic and membrane fractions, and
immunoblotted using an anti-GFP antibody. The graphs show mean +/- S.E.M. from
three independent experiments. Significant differences between control and drug
treated cells were assessed using one-way ANOVA tests.
*, p<0.05; **, p<0.01. N.S. – not significant
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II.

Elucidating the Mechanism of Action of Compounds 32 and 101.

A. Monoamine oxidase inhibitors

The structures of compound 32 and compound 101 are derived from the
general chalcone structure. Many chalcone derivatives have been shown to
be inhibitors of the enzyme monoamine oxidase (MAO) (Chimenti et al.,
2009). Since the structures of compounds 32 and 101 were based on
compounds designed to target MAO-B, we examined their inhibitory activity
against MAO enzymes to determine if their mode of action for K-Ras plasma
membrane mislocalization is through MAO inhibition.
To begin, MDCK cells stably expressing GFP-K-RasG12V were treated with
compound 32 or 101 for 48h. Whole cell lysates were harvested and a
monoamine oxidase assay was conducted. Briefly, an MAO substrate, ptyramine was added to cell lysates, and converted to its corresponding
aldehyde and H2O2 by endogenous MAO (Herraiz et al., 2018). The H2O2
further interacts with horseradish peroxidase (HRP) and Amplex red reagent
to produce resorufin. An increase in resorufin is indicative of increased H 2O2
levels. Therefore, MAO activity can be measured via resorufin levels.
For controls, inhibitors of MAO-A (clorgyline, and moclobemide) and MAO-B
(pargyline, 5-amino 2-methylindole (5A2M), and lazabemide) were tested.
Figure 14 shows that only one MAO-A inhibitor, moclobemide at 500µM,
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significantly inhibited resorufin production, whereas all of the MAO-B
inhibitors that were tested significantly reduced resorufin production in a
dose-dependent manner. While MAO-A is expressed in canine cells, it is
possible that there are no or very low MAO-A expression in MDCK cells,
making it difficult to detect their activity.
For our compounds, only compound 32 showed a significant decrease in
resorufin production, while compound 101 did not show any significant
changes. These data suggest that compound 32, but not 101 inhibits MAO
activity. Taken together with our confocal and fractionation assay (Figures 8,
9, and 13), our data suggest that the mechanism of action of compound 32
and 101 for K-Ras plasma membrane mislocalization is independent of MAO
inhibition.

51

Figure 14. Compound 32 inhibits MAO with 50
µM treatment. MDCK cells stably expressing GFPK-RasG12V were treated with an MAO-A inhibitor,
MAO-B inhibitor, compound 32, or compound 101
for 48h, harvested, and tested for MAO activity.
While only one MAO-A inhibitor showed a
decrease in resorufin levels (moclobemide) (A), all
of the MAO-B inhibitors showed significant
decrease in resorufin levels, indicating the
inhibition of MAO-B enzymatic activity (B).
Compound 32 showed significant decrease at 50
µM treatment (C). Compound 101 did not show
significant decrease at 25 or 50 µM. The graphs
show means +/- S.E.M. from three independent
experiments; significant differences between
control and drug treated cells were assessed using
one-way ANOVA tests. *, p<0.05; **, p<0.01.
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B. PKG signaling pathway

To explicate the mechanism by which K-Ras is phosphorylated, the cyclic
GMP-dependent protein kinase (PKG) pathway was considered. K-Ras has
been shown to be a PKG substrate, which phosphorylates K-Ras at residue
S181 (Cho, Casteel, et al., 2016). Activation of AMP-activated protein kinase
(AMPK) and endothelial nitric oxide synthase (eNOS) cause activation of PKG
leading to the phosphorylation of K-Ras (Cho, Casteel, et al., 2016).
To determine if compounds 32 and 101 activate this pathway, MDCK cells
stably expressing K-RasG12V were treated with the compounds at various
concentrations for 48h. Whole cell lysates were harvested and
immunoblotted to measure phosphorylation of AMPK and eNOS (Figure 15).
These data do not show any significant increase in pAMPK or peNOS that
would indicate an activation of this pathway. These data indicate that
compounds 32 and 101 mislocalize K-Ras from the plasma membrane
independent of the AMPK/eNOS signaling pathway.
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Figure 15. Compound 32
and compound 101 do not
activate the
AMPK/eNOS/PKG
pathway. MDCK KRasG12V cells were treated
with various
concentrations of
compound 32 (A) or
compound 101 (B) for 48h.
The whole cell lysates were
tested for levels of
phosphorylated AMPK and
eNOS through western blot
analysis. The graphs show
means +/- S.E.M. from
three independent
experiments. Significant
differences between
control and drug treated
cells were assessed using
one-way ANOVA tests.
*, p<0.05; **, p<0.01.
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C. PKC signaling pathway

PKG is not the only pathway in which K-Ras can be phosphorylated. Protein
kinase C (PKC) has also been shown to phosphorylate K-Ras, specifically at
Ser181 (Ballester, Furth, & Rosen, 1987; Bivona et al., 2006). Studies have
shown that PKC activation and subsequent K-Ras phosphorylation disrupts
interaction at the plasma membrane and mislocalizes K-Ras intracellularly
(Bivona et al., 2006). A chief target of PKC is myristoylated alanine-rich C
kinase substrate (MARCKS) (Fong, Yang, & Chen, 2017). MARCKS activation
was chosen to determine the activity of PKC for these experiments.
MDCK cells stably expressing GFP-K-RasG12V were treated with different
concentrations of compound 32 for 48h, and cell lysates were harvested and
immunoblotted for phospho-MARCKS levels. Compound 32 showed a
significant increase in pMARCKS levels at concentration 25 µM and over 2.5fold increase at 50 µM. These data suggest that compound 32 stimulates PKC
activity.
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Figure 16. pMARCKS levels increase with treatment of compound 32. MDCK cells stably
expressing GFP-K-RasG12V were treated with different concentrations of compound 32 for
48h. Cells were harvested, and lysates immunoblotted for phospho-MARCKS. There was a
significant increase in pMARCKS levels at concentrations 25 and 50 µM. This is indicative of an
activation in PKC, since MARCKS is a chief PKC target. The graphs show mean +/- S.E.M. from
three independent experiments. Blots are representative of three independent experiments.
GAPDH blot shown as loading control.
Significant differences between control and drug treated cells were assessed using one-way
ANOVA tests. *, p<0.05; **, p<0.01.
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III.

Characterizing the Anti-cancer Activity of Compounds 32 and 101 in lung
cancer cells.

A. Downstream signaling

Previous studies have shown that mislocalizing K-Ras from the plasma
membrane decreases the downstream signaling output, as well as induces
apoptosis in some cancer cells (Cho, Casteel, et al., 2016; Cho, Park, et al.,
2012; van der Hoeven et al., 2013). Ras activates Raf/MEK/ERK and PI3K/Akt
pathways. To determine if these compounds reduce K-Ras signaling, MDCK
cells stably expressing GFP-K-RasG12V or -H-RasG12V cells were treated with
compound 32 for 48h. Whole cell lysates were harvested and immunoblotted
for phosphorylated ERK and Akt levels. Figure 17A shows that compound 32
reduces ppERK (MAPK downstream effector) signaling by 48% and pAKT
(PI3K downstream effector) signaling by 35% at 50µM treatment. H-RasG12V
cells, however, do not show any significant changes in either signaling
pathway (Figure 17B). Taken together, these data suggest that compound 32
blocks oncogenic K-Ras, but not oncogenic H-Ras signaling.
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Figure 17. Compound 32 blocks oncogenic K-Ras but not H-Ras signal output. MDCK cells
expressing oncogenic K-Ras (A) or H-Ras (B) were treated with compound 32 for 48h; cell
lysates were blotted for phosphorylated ERK and Akt, Ras downstream effectors.
The graphs show mean +/- S.E.M. from three independent experiments. Blots are
representative of three independent experiments. GAPDH blot shown as loading control.
Significant differences between control and drug treated cells were assessed using one-way
ANOVA tests. *, p<0.05; **, p<0.01. N.S.- not significant.
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Additionally, MDCK K-RasG12V S181A cells were treated with compound 32
for 48h. These cells were harvested and immunoblotted for ppERK and pAKT.
Figure 18 shows that upon treatment, there was a slight increase in ppERK,
albeit, this increase was not statistically significant. There, also, was no
significant change in pAKT for these cells. This verifies the imaging data of
Figure 12 that shows when K-Ras cannot be phosphorylated at Ser181,
treatment with compound 32 does not alter its plasma membrane
localization. Congruently, treatment also does not alter the K-Ras ERK and
AKT downstream signaling pathways.
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Figure 18. Compound 32 does not block mutated K-RasG12V S181A signal output. Cell lysates
of MDCK cells expressing K-RasG12V S181A were blotted for phosphorylated ERK and Akt, Ras
downstream effectors.
The graphs show mean +/- S.E.M. from three independent experiments. Blots are
representative of three independent experiments. A GAPDH blot is shown as loading control.
Significant differences between control and drug treated cells were assessed using one-way
ANOVA tests. *, p<0.05; **, p<0.01. N.S.- not significant.
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B. Cell proliferation

To further validate the effects of compounds 32 and 101 on oncogenic K-Ras
signaling, we performed proliferation assays on non-small cell lung cancer
cells (NSCLCs). NSCLCs expressing wild-type K-Ras (H1975, H1299, H522) or
oncogenic K-Ras (A549, H441, H23, H358), as well as the non-cancerous
human lung epithelial cell line BEAS-2B, were treated with various
concentrations of either compound for 72h. After the treatment, cellular
DNA content was measured as a way of analyzing cell proliferation. Both
compounds 32 (Figure 19) and 101 (Figure 20) negatively affect proliferation
of NSCLCs harboring a K-Ras mutation versus wild-type K-Ras. However, the
one exception to this is the A549 cell line. This cell line’s proliferation was not
as affected as the other oncogenic K-Ras mutant cell lines. Both compounds
32 and 101 had a negative effect on the proliferation of the non-cancerous
human lung epithelial cell line BEAS-2B.
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Figure 19. The effect of compound 32 on proliferation. NSCLCs harboring oncogenic
mutant K-Ras, wild-type K-Ras, or a non-cancerous human lung epithelial cell line, BEAS-2B
(highlighted in red), were treated with different concentrations of compound 32. The cells
were treated for a total of 72h and given freshly treated media every 24h. The cellular DNA
content was measured to analyze proliferation.
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Figure 20. The effect of compound 101 on proliferation. NSCLCs harboring oncogenic
mutant K-Ras, wild-type K-Ras, or a non-cancerous human lung epithelial cell line, BEAS-2B
(highlighted in red), were treated with different concentrations of compound 101. The cells
were treated for a total of 72h and given freshly treated media every 24h. The cellular DNA
content was measured to analyze proliferation.

63

Discussion and Future Directions

There is currently no Ras-specific treatment in clinic (Papke & Der, 2017). Since
oncogenic Ras is found in about 25% of all human cancers and K-Ras is the most
frequently mutated isoform of Ras, finding a K-Ras-specific treatment is of the upmost
importance within the cancer community (Prior et al., 2012; Stephen et al., 2014). Here,
we have taken a close look at how two chalcone-derived compounds affect oncogenic KRas. Chalcones are naturally occurring and have been shown to have anti-cancer
properties (Bandgar et al., 2010). Manipulating the constituent groups can alter the
chalcones’ efficacies. Our goal in using novel, lab-synthesized chalcones is to be able to
directly target our protein of interest, K-Ras, by disrupting its interaction with the
plasma membrane, which is a viable way of targeting oncogenic mutant K-Ras driven
cancers.
Our approach to examine the anti-K-Ras activity of chalcones is to study K-Ras
interaction with the plasma membrane after drug treatment. Since Ras proteins must
interact with the plasma membrane for biological activity, compounds that dissociate
Ras from the plasma membrane could be a good starting point for developing anti-Ras
drugs (Hancock, 2003; Willumsen et al., 1984). In this study, both compound 32 and 101
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were shown to mislocalize K-Ras, but not H-Ras, making them K-Ras-specific. We also
revealed that compounds 32 and 101 increase K-Ras accumulation in the cytosol.
Compounds 32 and 101 were originally designed to target MAO. However, we have
shown that although compound 32 showed inhibitory activity against MAO, compound
101 did not. Since both compounds mislocalize K-Ras from the plasma membrane, these
data suggest that K-Ras mislocalization by compounds 32 and 101 is independent of
MAO inhibition.
Two molecular mechanisms have been identified to dissociate K-Ras from the plasma
membrane: disrupting cellular PS distribution and levels, and enhancing K-Ras
phosphorylation (Bivona et al., 2006; Cho, Casteel, et al., 2016; Cho, Park, et al., 2012;
Cho, van der Hoeven, et al., 2016). K-Ras localizes with PS at the plasma membrane and
decreasing PS levels at the plasma membrane has been shown to mislocalize K-Ras (Cho,
Park, et al., 2012; Cho, van der Hoeven, et al., 2016). Using LactC2 as a PS marker, we
have shown that compounds 32 and 101 do not disrupt cellular distribution of PS,
suggesting the mechanism of action of compounds 32 and 101 for dissociating K-Ras
from the plasma membrane is independent of PS distribution. Furthermore, we have
shown that blocking K-Ras phosphorylation of Ser181 nullifies the mislocalizing effects
of both compounds, suggesting compound 32 and 101 dissociate K-Ras from the plasma
membrane through phosphorylation of K-Ras at Ser181. To further validate, the extent
of K-Ras phosphorylation needs to be measured after the drug treatment using a K-Ras
phosphorylation assay (Cho, Casteel, et al., 2016).
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Activation of the AMPK/eNOS/PKG signaling pathway phosphorylates K-Ras at Ser181,
leading to its mislocalization from the plasma membrane (Cho, Casteel, et al., 2016). To
determine if compounds 32 and 101 affect the activation of the AMPK/eNOS/PKG
pathway, we measured phosphorylation of AMPK and eNOS levels. Both compounds did
not affect phosphorylation of AMPK or eNOS, suggesting these compounds do not
mislocalize K-Ras from the plasma membrane via the AMPK/eNOS/PKG signaling
pathway. However, it is possible that compounds 32 and 101 alternatively activate PKG.
To test this possibility, K-Ras plasma membrane localization could be studied in cancer
cells treated with compounds 32 or 101 after knocking down PKG using siRNA (Cho,
Casteel, et al., 2016). If K-Ras is not mislocalized, then PKG is activated by these
compounds; if K-Ras is mislocalized, then the phosphorylation of Ser181 is independent
of PKG. Congruently, chalcones have been shown to have antioxidant capabilities and
suppress nitric oxide (NO) production, which could be a factor if PKG is not activated
(Jung et al., 2017).
PKC is also reported to phosphorylate K-Ras at Ser181, resulting in K-Ras plasma
membrane mislocalization (Bivona et al., 2006). To test if PKC is responsible for
phosphorylating K-Ras with compound 32 and 101 treatment, phosphorylation of
MARCKS, a PKC downstream effector, was measured. Following treatment of cells with
compound 32, there was a dose dependent increase in pMARCKS, indicating an increase
in PKC activity. To further characterize the activation of PKC by compound 32, different
PKC isoforms will need to be tested as well. There are three groups of PKC isoforms:
conventional, novel, and atypical (Newton, 1995). The conventional isoforms are PKCα,
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PKCβI, PKCβII, and PKCγ, and are the only isoforms that are regulated by Ca2+ (Newton,
1995). I hypothesize that one of these conventional PKC isoforms phosphorylates K-Ras,
since Ca2+ regulates these PKC isoforms, and K-Ras binds with the calcium sensor,
calmodulin (Newton, 1995; Sorensen et al., 2013; Stephen et al., 2014).
While we have documented the anticancer activity of compounds 32 and 101 by
inhibiting proliferation of oncogenic K-Ras-driven NSCLCS, we have also shown that
compounds 32 and 101 also inhibited the growth of a non-cancerous human lung
epithelial cell line, BEAS-2B. It is unclear at this time why these cells are sensitive to the
treatment. There could be an as yet unknown activated pathway that causes this cell
line to be sensitive to these two compounds. More non-cancerous human lung epithelial
cell lines need to be treated with these compounds to determine if this is a unique case,
or universal for non-cancerous human lung epithelial cells.
Moreover, A549 cells harboring oncogenic mutant K-Ras were not inhibited by
treatment with either compound. A549 cell line is homozygous for the K-RasG12S
mutation. Here, glycine, a small non-polar amino acid, is mutated to the polar amino
acid, serine. It has already been established that G12V and G12D mutations can lead to
activation of different signaling pathways (Ihle et al., 2012). It is therefore plausible that
this G12S mutation instigates a different signaling pathway than the G12C mutation of
the H23 and H358 cell lines, or the G12V mutation of the H441 cell line. To compare,
another cell line with the G12S homozygous mutation should be tested. Furthermore,
current therapies against NSCLCS, such as the EGFR inhibitor erlotinib (Tarceva,
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Genentech) could be tested to determine if our compounds are as potent as current
therapies.
A possible future direction of this project could look at the synergism of compounds 32
or 101 with other drugs that mislocalize K-Ras from the plasma membrane with
different mechanisms of action. For example, metformin mislocalizes K-Ras from the
plasma membrane through K-Ras phosphorylation at Ser181 by PKG (Cho, Casteel, et al.,
2016). If the mechanism of action for compounds 32 or 101 is verified to be through
phosphorylation by PKC, then a synergistic approach that activates both PKG and PKC
pathways could be a more beneficial treatment than only activating one pathway.
Similarly, co-treatment of compound 32 or 101 with fendiline, which mislocalizes K-Ras
from the plasma membrane by reducing PS levels in the plasma membrane, could
potentiate the efficacy of our compounds in K-Ras plasma membrane mislocalization
(Cho, van der Hoeven, et al., 2016).
In conclusion, we have identified a new set of compounds that mislocalize K-Ras from
the plasma membrane through inhibition of K-Ras phosphorylation at Ser181. These
compounds inhibit K-Ras signal output as well as the growth of NSCLCs harboring
oncogenic mutant K-Ras. Further characterization of their molecular mechanism could
be a good starting point to develop an anti-K-Ras drug.
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